AKYA vs. PRLD, STRO, NAUT, SEER, ATHA, BNGO, ABUS, LAB, CTKB, and QTRX
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Prelude Therapeutics (PRLD), Sutro Biopharma (STRO), Nautilus Biotechnology (NAUT), Seer (SEER), Athira Pharma (ATHA), Bionano Genomics (BNGO), Arbutus Biopharma (ABUS), Standard BioTools (LAB), Cytek Biosciences (CTKB), and Quanterix (QTRX). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
Akoya Biosciences has higher revenue and earnings than Prelude Therapeutics. Akoya Biosciences is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
Akoya Biosciences received 1 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 59.09% of users gave Akoya Biosciences an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
Akoya Biosciences currently has a consensus target price of $9.07, indicating a potential upside of 93.42%. Prelude Therapeutics has a consensus target price of $5.25, indicating a potential upside of 10.76%. Given Akoya Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Akoya Biosciences is more favorable than Prelude Therapeutics.
In the previous week, Akoya Biosciences had 6 more articles in the media than Prelude Therapeutics. MarketBeat recorded 7 mentions for Akoya Biosciences and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.89 beat Akoya Biosciences' score of 0.60 indicating that Prelude Therapeutics is being referred to more favorably in the news media.
79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 8.5% of Akoya Biosciences shares are owned by company insiders. Comparatively, 79.5% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Prelude Therapeutics has a net margin of 0.00% compared to Akoya Biosciences' net margin of -65.53%. Prelude Therapeutics' return on equity of -53.39% beat Akoya Biosciences' return on equity.
Summary
Akoya Biosciences beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Akoya Biosciences Competitors List
Related Companies and Tools